Aligning with the Trump administration’s push to lessen the nation’s dependence on foreign pharmaceutical manufacturing, the FDA has launched a new initiative intended to streamline the establishment of domestic production sites.
The new FDA PreCheck program will utilize a two-stage method to facilitate the creation of new pharmaceutical production facilities across the U.S.
The first phase of the program, which the FDA has named the Facility Readiness Phase, allows manufacturers to interact more often with the regulatory agency at vital points of development, such as building design and construction.
The FDA stated that during this phase, firms will be urged to supply thorough details regarding their planned manufacturing locations, encompassing aspects like layouts and quality assurance plans.
The regulator suggests that pharmaceutical manufacturers submit these details using a Drug Master File specifically for the facility. This document could then be utilized to back future applications for drug approval.
As for the program’s subsequent stage, its purpose is to make the portion of a company’s facility application dedicated to chemistry, production,and controls more efficient. The FDA aims to achieve this by providing early feedback and arranging pre-application discussions.
FDA Commissioner Marty Makary, remarked that the nation’s increasing dependence on overseas drug production had introduced risks to national security. He explained that the FDA PreCheck initiative was among several measures the agency was pursuing to reduce this reliance and secure a robust, reliable, and domestic pharmaceutical supply for Americans.
The FDA is set to convene a public session at the end of September to examine the PreCheck initiative in more depth and gather input regarding existing challenges to onshoring.
Having more production in the U.S. has been a key element of President Donald Trump’s trade agenda in his second term, with the prospect of drug import tariffs already triggering numerous significant investment declarations within the life sciences sector.
The FDA’s PreCheck initiative emerges as a direct reaction to Trump’s May executive directive urging the agency to ease regulatory obstacles for U.S.-based drug producers.
The directive explicitly instructed the FDA to shorten the approval timeline for domestic pharmaceutical manufacturing facilities while also raising fees for, and increasing the inspection rate of, overseas production locations.
Both the executive order and the newly introduced PreCheck initiative provide few specifics on how expedited facility approval procedures will function in reality, yet they signal that the administration recognizes at least one significant barrier to relocating manufacturing to the U.S.
Specifically, establishing production plants is generally a multi-year endeavor. In the initial phase of Trump’s second term, industry observers have noted that the U.S. policy landscape would require a substantial transformation to enable the swift and large-scale manufacturing expansion the administration has in mind.
Nevertheless, the leverage of import tariffs has already convinced numerous pharmaceutical firms to commit multi-billion-dollar investments within the country.
The most substantial expenditure comes from J&J, which has vowed to channel $55 billion into its American operations. AstraZeneca and Roche have allocated $50 billion each toward U.S. projects, while Eli Lilly has committed $27 billion.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
